Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Celldex Therapeutics (NQ: CLDX )

37.46 -1.65 (-4.22%)
Streaming Delayed Price Updated: 3:26 PM EDT, Mar 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 957,079
Open 38.77
Bid (Size) 37.41 (1)
Ask (Size) 37.51 (4)
Prev. Close 39.11
Today's Range 36.88 - 38.77
52wk Range 19.85 - 48.40
Shares Outstanding 47,207,189
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Celldex Reports Fourth Quarter and Year End 2022 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via Globe NewsWire
Union Pacific, Kosmos Energy, Fisker And Other Big Stocks Moving Higher On Monday
U.S. stocks traded higher, with the Dow Jones gaining more than 300 points on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga

Performance

YTD
-13.67%
-13.67%
1 Month
-10.96%
-10.96%
3 Month
-10.55%
-10.55%
6 Month
+24.62%
+24.62%
1 Year
+10.24%
+10.24%

More News

Read More
Why Celldex Therapeutics Shares Are Trading Higher Today
Via Benzinga
Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at AAAAI 2023
From Celldex Therapeutics, Inc.
Via Globe NewsWire
Celldex Therapeutics Earnings Perspective: Return On Capital Employed
Via Benzinga
Read How Cantor Views Celldex Therapeutics' Barzolvolimab Data
Via Benzinga
Celldex Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
From Celldex Therapeutics, Inc.
Via Globe NewsWire
Celldex Therapeutics to Present at SVB Securities Global Biopharma Conference
From Celldex Therapeutics, Inc.
Via Globe NewsWire
Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2023
From Celldex Therapeutics, Inc.
Via Globe NewsWire
Celldex's Barzolvolimab Shows Rapid, Durable Responses In Early Urticaria Study
Via Benzinga
These '20 Stocks To Watch' Moved On Last Fed Rate Hike: How Will They React Today?
Via Benzinga
BriaCell’s Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients
Via News Direct
Topics Death
Exposures Death
BriaCell’s Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients
Via TheNewswire.com
Topics Death
Exposures Death
BriaCell's Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients
Via Benzinga
Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Inducible Urticaria at Global Urticaria Forum 2022
From Celldex Therapeutics, Inc.
Via Globe NewsWire
Celldex Therapeutics Announces Multiple Upcoming Presentations of Barzolvolimab Data at GA²LEN Global Urticaria Forum (GUF) 2022
From Celldex Therapeutics, Inc.
Via Globe NewsWire
Celldex to Participate in Upcoming November Investor Conferences
From Celldex Therapeutics, Inc.
Via Globe NewsWire
Celldex Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via Globe NewsWire
Celldex Therapeutics Earnings Perspective: Return On Capital Employed
Via Benzinga
Accolade Shares Jump Around 29%, Here's 75 Biggest Movers From Friday
Via Benzinga
HC Wainwright & Co. Maintains Buy Rating for Celldex Therapeutics: Here's What You Need To Know
Via Benzinga
Why Is Akebia Therapeutics Surging By 28%? 48 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Celldex Therapeutics Skids As It Takes On A Blockbuster Roche, Novartis Drug
Via Investor's Business Daily
Why U.S. Stocks Are Trading Higher, Manufacturing Report And More
Via Benzinga
Recap of Tuesday's Biotech Catalysts - End of the Day Summary
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.